2025-26 ICER Assessments

The Institute for Clinical Economic Review (ICER) conducts cost effectiveness studies for insurers using the cost-per-QALY methodology. ICER provides guidance on its website for patients and patient advocates to provide direct input related to their experiences with the disease. Click here to provide patient input. Click here to view the topics and deadlines.

View PIPC value assessment resources on gene therapies here, on health equity here and an analysis on lack of patient-centered outcomes in value assessment here.

• IgA Nephropathy: Research Protocol available. Public meeting: February 2026.

• Launch Price and Access Report: Drug Approvals from 2023-2024: Protocol available.

• Smoking Cessation: Model Analysis Plan available. Public meeting: January 2026.

• Obesity Management: Draft Evidence Report available. Public comments due October 6, 2025 (TODAY). Public meeting: November 2025.

• Examining Strategies to Ensure Affordable Access for Obesity Medications: White Paper published on April 9, 2025.

• Non-Cystic Fibrosis Bronchiectasis: Evidence Report and Evidence Presentation available. Public meeting: September 2025.

• Spinal Muscular Atrophy: Final Evidence Report and Meeting Summary available.

• Multiple Sclerosis — SPMS: Final Evidence Report and Meeting Summary available.

• Retinitis Pigmentosa: Final Evidence Report and Meeting Summary available.